Galitzer Hillel 4

What Happened Hillel Galitzer, Chief Operating Officer of Entera Bio Ltd. (ENTX), received a grant of 72,993 stock‑settled restricted stock units (RSUs) on May 7, 2026. The Form 4 lists the acquisition price as $0 (award/grant code A), reflecting a compensation grant rather than a market purchase or sale.

Key Details

• Transaction date: May 7, 2026; Form 4 filed May 8, 2026 (timely under Form 4 rules).
• Transaction type/code: Award/Grant (A); 72,993 RSUs granted; acquisition price shown as $0 on the filing.
• Vesting: RSUs vest ratably quarterly over one year, beginning May 1, 2026 (per filing footnote).
• Reason: Grant awarded in lieu of a cash bonus (approved by the Board).
• Shares owned after transaction: Not specified in the filing.

Context This was a compensation grant (RSUs) rather than a cash purchase or sale. RSU grants are a common form of executive pay and vesting delays ownership transfer; they do not by themselves indicate insider buying or selling intent. Because the award replaces a cash bonus, it’s primarily a payroll/compensation item rather than an investment transaction.